Apple Health PDL Drug Policy Motions



Antivirals – HIV Combinations

- ▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 12.10.99-2 as recommended.
 - ► Add criteria addressing renal function decline by 25%
 - Add clarification for mental illness poorly controlled

Motion: Park

2nd: Flatebo



Antivirals: HIV- emtricitabine/tenofovir alafenamide (Descovy)

- ▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 12.10.99.02-2 as recommended.
 - ► Add criteria addressing renal function decline by 25%
 - Add clarification for mental illness poorly controlled

Motion: Schwilke

2nd: Park



Agents for ALS – Edaravone (Radicava)

- ▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 74.50.90-1 as recommended.
 - Remove forced vital capacity criteria
 - Review recommendations and re-present at next DUR meeting

- Motion:
- **2**nd:



Pulmonary Hypertension (PH) Agents (Oral/Inhalation)

- ▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 40.12.00-2 as recommended.
 - ► Add language referencing preferred product pathway
 - Review recommendations and re-present at next DUR meeting

- Motion:
- **2**nd:



Cystic Fibrosis Agents (Oral)

- ▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 45.30.00-2 as recommended.
 - Remove lung transplant criteria

Motion: Storhaug

○ 2nd: Marcotte



Analgesics: Opioid Agonists

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 65.10.00 as recommended.

Motion: Lee

○ 2nd: Flatebo

